New cocktail aims to shrink sarcomas: bevacizumab joins chemo in phase 2 trial
NCT ID NCT07547592
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the drug bevacizumab (Onbevzi) to standard chemotherapy (gemcitabine and docetaxel) can shrink tumors better than chemo alone in people with advanced soft tissue sarcoma. About 92 adults who have already had 1-2 prior chemotherapies will be randomly assigned to one of two groups. The main goal is to see how many patients' tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bevacizumab (Onbevzi), gemcitabine, docetaxel
- What this could lead to
- If adding bevacizumab works, this could give doctors a new, more effective drug combination for treating advanced soft tissue sarcoma.
- What could go wrong
- This is a mid-stage trial with only 92 people, so results may not apply to everyone. Adding bevacizumab also raises risks like bleeding and high blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Blood test may spot hidden sarcoma signals
- New pill may keep soft tissue sarcoma in check after chemo
- Immunotherapy boosts chemo against rare sarcomas?
- New drug takes aim at Hard-to-Treat sarcoma
- Dietary change explored as cancer support strategy